Effectiveness and safety of subcutaneous abatacept in biologic-naïve RA patients at Week 52: A Japanese multicentre investigational study (ORIGAMI study).
Naoto TamuraTakanori AzumaKenta MisakiRei YamaguchiFuminori HiranoEiji SugiyamaDaisuke KanaiYohko MurakawaMotohiro OribeTakahito KimataKazutoshi AokiTomoko SugiuraKoji TakasugiYuya TakakuboYasuyuki TomitaTakeo IsozakiToshihiro NankiNaooki KatsuyamaTakanori KuroiwaHideto OshikawaMotohide KanekoHiroshi FujinagaKiwamu SaitoEiichi TanakaEisuke InoueYuri YoshizawaShigeru MatsumotoHisashi YamanakaMasayoshi HarigaiPublished in: Modern rheumatology (2022)
Abatacept significantly improved disease activity, physical disability, and quality of life for up to 52 weeks in RA patients in a real-world setting.
Keyphrases
- rheumatoid arthritis
- disease activity
- rheumatoid arthritis patients
- ankylosing spondylitis
- systemic lupus erythematosus
- end stage renal disease
- mental health
- juvenile idiopathic arthritis
- newly diagnosed
- physical activity
- interstitial lung disease
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- cross sectional
- study protocol